Category

Archives

PARP

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines

15 views | Jun 10 2022

André Fedier et al. found that olaparib exposure was unlikely to produce an acquired resistance phenotype and that PARPi‑sensitive ovarian cancer cells were also cross‑sensitive to non‑platinum and even to compounds not directly interacting with the DNA. [Read the Full Post]

Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management

41 views | May 27 2022

Seyed Behzad Jazayeri et al. thought that olaparib and rucaparib had shown clinical benefit in heavily pretreated patients with mCRPC and DNA repair mutation genes. [Read the Full Post]

Imaging PARP with [ 18 F]rucaparib in pancreatic cancer models

30 views | May 26 2022

Chung Ying Chan et al. demonstrated the potential of [18F]rucaparib as a non-invasive PARP-targeting imaging agent for pancreatic cancers. [Read the Full Post]

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

35 views | May 24 2022

Xuan Liu et al. indicated that the deep analysis of pre-treatment tumors could identify biomarkers that were predictive of response to talazoparib and potentially other PARP inhibitors. [Read the Full Post]

Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations

22 views | May 23 2022

Chwayita Mgoboza et al. found that binding residues with total binding energy greater than 1.00 kcal/mol contributed considerably to the Talazoparib's binding activities on PARP-1 and PARP-16. [Read the Full Post]

The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events

39 views | May 16 2022

Santosh Timilsina et al. designed an ongoing clinical trial, where they were testing the efficacy of imipramine for treating patients with triple-negative and estrogen receptor-positive breast cancer. [Read the Full Post]

Proangiogenesis effects of compound danshen dripping pills in zebrafish

72 views | Apr 24 2022

Yang-Xi Hu et al. found that CDDP had a proangiogenic effect, the mechanism of which involved the VEGF/VEGFR and PI3K/AKT signaling pathways. [Read the Full Post]

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia

108 views | Apr 15 2022

Emanuela M Ghia et al. found that Wnt5a-induced ROR1-signaling can enhance resistance to venetoclax therapy. [Read the Full Post]

Effect of High Cholesterol Regulation of LRP1 and RAGE on Aβ Transport Across the Blood-brain Barrier in Alzheimer's Disease

568 views | Sep 11 2021

Rui Zhou et al. found that high cholesterol decreased LRP1 expression and increased RAGE expression in cerebral microvascular endothelial cells, which led to Aβ transport disorder in the blood-brain barrier. [Read the Full Post]

Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma

505 views | Aug 23 2021

Irene Paterniti et al. indicated PARP inhibitors as adjuvants for therapeutic strategy of oral cancer. [Read the Full Post]